Review



skmel28 human  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC skmel28 human
    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from <t>SKMEL28</t> and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.
    Skmel28 Human, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 2175 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pmc13113566-59-2-17?v=ATCC
    Average 99 stars, based on 2175 article reviews
    skmel28 human - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAF V600E -Associated Mitochondrial Division in Cancer"

    Article Title: A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAF V600E -Associated Mitochondrial Division in Cancer

    Journal: Antibodies

    doi: 10.3390/antib15020038

    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from SKMEL28 and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.
    Figure Legend Snippet: Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from SKMEL28 and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.

    Techniques Used: Recombinant, Generated, Western Blot, Membrane, Isolation, Molecular Weight, Expressing, Quantitative RT-PCR, Knockdown, SDS Page, Phospho-proteomics, Control

    Oncogenic MAPK-regulated DRP1-S616Ⓟ expression is detected by recombinant 3G11. ( A ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green; mitochondria) and Hoechst 33342 (blue; nuclei). Scale bars = 10 microns. ( B ) SKMEL28 cells were studied as in ( A ). Mitochondrial networks are shown as maximum intensity projections of super-resolution Leica LIGHTNING deconvolved confocal z-stacks. Imaris surface features were used to generate 3D projections to visualize changes in mitochondrial network architecture. Scales bars = 5 microns. ( C ) Mitochondrial elongation was quantified using the Perimeter: Area Ratio. ( D , E ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green), DRP1-S616Ⓟ (red), and Hoechst 33342 (blue). Red channel intensity was quantified to assess DRP1-S616Ⓟ signal intensity using Mander’s coefficient. Scale bars = 10 microns. Zoomed network images (white dashed box) = 50 micron scale bars. ( F , G ) A375 cells were analyzed as panels ( D , E ). All experiments were performed at least twice, with statistical significance determined from a minimum of two independent experiments using a one-way ANOVA test. ** refers to a p value ≤ 0.01 and **** refers to a p value ≤ 0.0001.
    Figure Legend Snippet: Oncogenic MAPK-regulated DRP1-S616Ⓟ expression is detected by recombinant 3G11. ( A ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green; mitochondria) and Hoechst 33342 (blue; nuclei). Scale bars = 10 microns. ( B ) SKMEL28 cells were studied as in ( A ). Mitochondrial networks are shown as maximum intensity projections of super-resolution Leica LIGHTNING deconvolved confocal z-stacks. Imaris surface features were used to generate 3D projections to visualize changes in mitochondrial network architecture. Scales bars = 5 microns. ( C ) Mitochondrial elongation was quantified using the Perimeter: Area Ratio. ( D , E ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green), DRP1-S616Ⓟ (red), and Hoechst 33342 (blue). Red channel intensity was quantified to assess DRP1-S616Ⓟ signal intensity using Mander’s coefficient. Scale bars = 10 microns. Zoomed network images (white dashed box) = 50 micron scale bars. ( F , G ) A375 cells were analyzed as panels ( D , E ). All experiments were performed at least twice, with statistical significance determined from a minimum of two independent experiments using a one-way ANOVA test. ** refers to a p value ≤ 0.01 and **** refers to a p value ≤ 0.0001.

    Techniques Used: Expressing, Recombinant, Staining



    Similar Products

    99
    ATCC skmel28 human
    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from <t>SKMEL28</t> and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.
    Skmel28 Human, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pmc13113566-59-2-17?v=ATCC
    Average 99 stars, based on 1 article reviews
    skmel28 human - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC 110 skmel28 human melanoma cell line
    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from <t>SKMEL28</t> and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.
    110 Skmel28 Human Melanoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pm41275493-905-21-30?v=ATCC
    Average 99 stars, based on 1 article reviews
    110 skmel28 human melanoma cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC skmel28 male human melanoma cell line
    Reagents used in this study
    Skmel28 Male Human Melanoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pmc11960706-83-0-7?v=ATCC
    Average 99 stars, based on 1 article reviews
    skmel28 male human melanoma cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC human cell line skmel28

    Human Cell Line Skmel28, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pmc11937654-27-0-5?v=ATCC
    Average 99 stars, based on 1 article reviews
    human cell line skmel28 - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC cell lines human cell line skmel28 atcc cat

    Cell Lines Human Cell Line Skmel28 Atcc Cat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pm40088451-86-117-123?v=ATCC
    Average 99 stars, based on 1 article reviews
    cell lines human cell line skmel28 atcc cat - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC human melanoma skmel28 cell line

    Human Melanoma Skmel28 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pm40038749-41-1-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    human melanoma skmel28 cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC 1993 cvcl 4633 skmel28 male human melanoma cell line atcc fogh

    1993 Cvcl 4633 Skmel28 Male Human Melanoma Cell Line Atcc Fogh, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel28+human/pm40015991-300-51-59?v=ATCC
    Average 99 stars, based on 1 article reviews
    1993 cvcl 4633 skmel28 male human melanoma cell line atcc fogh - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    Image Search Results


    Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from SKMEL28 and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.

    Journal: Antibodies

    Article Title: A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAF V600E -Associated Mitochondrial Division in Cancer

    doi: 10.3390/antib15020038

    Figure Lengend Snippet: Hybridoma screenings and recombinant 3G11 antibody evaluation. ( A ) Hybridomas generated from the top five anti-sera were evaluated for specificity using Western blot analysis of full-length recombinant GST-DRP1 ± ERK1 treatment. 100 ng of recombinant GST-DRP1 was loaded per lane. Total DRP1 was evaluated for equal protein loading. ( B , C ) The hybridomas were screened using Western blot analysis of whole cell lysates (100 µg/lane; ( B )) or heavy membrane fractions (25 µg/lane; ( C )) isolated from SKMEL28 and A375 cells treated with GSK1120212 (50 nM; GSK), PLX4032 (1 µM; PLX), or DMSO for 6 h. Total DRP1 was evaluated for equal protein loading. ( D ) Primary melanoma lines were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h. Whole cell lysates were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( E ) A375 and SKMEL28 were treated with GSK1120212 (50 nM) or PLX4032 (1 µM) for 6 h and evaluated as in D . Recombinant 3G11 was evaluated for DRP1-S616Ⓟ detection. Actin was probed for equal protein loading. ( F ) Heavy membrane fractions from the same treatments in D were Western blotted for the indicated proteins. Recombinant 3G11 was evaluated for DRP1-S616Ⓟ. HSP60 was probed for equal protein loading. Molecular weight standards for all Western blots are indicated in kilodaltons (kDa). ( G , H ) YUPEET cells expressing two independent shRNAs targeting DNM1L (sh1, sh2), or their combination, were analyzed by RT-qPCR and Western blot to determine DNM1L knockdown and loss of detection by recombinant 3G11. ( I ) YUPEET cells were treated with GSK1120212 (50 nM) or DMSO for 6 h, and whole cell lysates were evaluated by SDS-PAGE and Western blot for the indicated proteins to assess the specificity of recombinant 3G11 for DRP1-S616 phosphorylation relative to S637. Actin was used as a loading control. ( J ) YUPEET cell lysates were treated with λ-phosphatase for 30 min prior to SDS-PAGE and Western blot analysis. Actin was used as a loading control. ( K ) Untreated whole cell lysates (25 and 50 μg) from YUPEET cells were analyzed by SDS-PAGE and Western blot to compare the sensitivity of recombinant 3G11 and the Cell Signaling Technology (CST) antibody. Total DRP1 and actin were used as loading controls. Data are representative of three independent experiments.

    Article Snippet: A375 and SKMEL28 human-derived non-primary (i.e., lymph node and secondary metastasis-derived, respectively) melanoma lines were purchased from ATCC and cultured in DMEM media.

    Techniques: Recombinant, Generated, Western Blot, Membrane, Isolation, Molecular Weight, Expressing, Quantitative RT-PCR, Knockdown, SDS Page, Phospho-proteomics, Control

    Oncogenic MAPK-regulated DRP1-S616Ⓟ expression is detected by recombinant 3G11. ( A ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green; mitochondria) and Hoechst 33342 (blue; nuclei). Scale bars = 10 microns. ( B ) SKMEL28 cells were studied as in ( A ). Mitochondrial networks are shown as maximum intensity projections of super-resolution Leica LIGHTNING deconvolved confocal z-stacks. Imaris surface features were used to generate 3D projections to visualize changes in mitochondrial network architecture. Scales bars = 5 microns. ( C ) Mitochondrial elongation was quantified using the Perimeter: Area Ratio. ( D , E ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green), DRP1-S616Ⓟ (red), and Hoechst 33342 (blue). Red channel intensity was quantified to assess DRP1-S616Ⓟ signal intensity using Mander’s coefficient. Scale bars = 10 microns. Zoomed network images (white dashed box) = 50 micron scale bars. ( F , G ) A375 cells were analyzed as panels ( D , E ). All experiments were performed at least twice, with statistical significance determined from a minimum of two independent experiments using a one-way ANOVA test. ** refers to a p value ≤ 0.01 and **** refers to a p value ≤ 0.0001.

    Journal: Antibodies

    Article Title: A Recombinant Antibody Against Human DRP1 Serine 616 Phosphorylation Enables Detection of BRAF V600E -Associated Mitochondrial Division in Cancer

    doi: 10.3390/antib15020038

    Figure Lengend Snippet: Oncogenic MAPK-regulated DRP1-S616Ⓟ expression is detected by recombinant 3G11. ( A ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green; mitochondria) and Hoechst 33342 (blue; nuclei). Scale bars = 10 microns. ( B ) SKMEL28 cells were studied as in ( A ). Mitochondrial networks are shown as maximum intensity projections of super-resolution Leica LIGHTNING deconvolved confocal z-stacks. Imaris surface features were used to generate 3D projections to visualize changes in mitochondrial network architecture. Scales bars = 5 microns. ( C ) Mitochondrial elongation was quantified using the Perimeter: Area Ratio. ( D , E ) SKMEL28 cells were treated with GSK1120212 (50 nM) for 16 h, fixed, and stained for TOMM20 (green), DRP1-S616Ⓟ (red), and Hoechst 33342 (blue). Red channel intensity was quantified to assess DRP1-S616Ⓟ signal intensity using Mander’s coefficient. Scale bars = 10 microns. Zoomed network images (white dashed box) = 50 micron scale bars. ( F , G ) A375 cells were analyzed as panels ( D , E ). All experiments were performed at least twice, with statistical significance determined from a minimum of two independent experiments using a one-way ANOVA test. ** refers to a p value ≤ 0.01 and **** refers to a p value ≤ 0.0001.

    Article Snippet: A375 and SKMEL28 human-derived non-primary (i.e., lymph node and secondary metastasis-derived, respectively) melanoma lines were purchased from ATCC and cultured in DMEM media.

    Techniques: Expressing, Recombinant, Staining

    Reagents used in this study

    Journal: Genes & Development

    Article Title: Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression

    doi: 10.1101/gad.351985.124

    Figure Lengend Snippet: Reagents used in this study

    Article Snippet: SKmel28 (male) human melanoma cell line , ATCC , , CVCL_0526.

    Techniques: Software, Transduction, Virus, Subcloning, Bacteria, Recombinant, Bradford Assay, Protease Inhibitor, RNA Extraction, Reporter Assay, Bicinchoninic Acid Protein Assay, Quantitative RT-PCR, Negative Control

    Journal: STAR Protocols

    Article Title: Protocol for high-precision CRISPR-Cas12a-based SNV detection on synthetic DNA, cell line cfDNA models, and liquid biopsies

    doi: 10.1016/j.xpro.2025.103696

    Figure Lengend Snippet:

    Article Snippet: Human cell line SKmel28 , ATCC , Cat#HTB-72; RRID: CVCL_0526.

    Techniques: Recombinant, Modification, Purification, Variant Assay, Amplification, Software